Phase 1b/2 Study of JNJ-90014496 for B-Cell Non-Hodgkin Lymphoma Initiated by Janssen
Janssen is conducting Phase 1b/2 study of prizloncabtagene autoleucel, CAR T-cell therapy targeting CD20 and CD19 in B-NHL.
Phase III
B-Cell Non-Hodgkin Lymphoma
Status
Initiated
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of this Phase 1b/2 study by Janssen is significant as it targets a critical patient population in the oncology space. Success in this trial could bolster Janssen's competitive position in the CAR T-cell therapy market, which is rapidly evolving and highly competitive.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial progress and outcomes, particularly efficacy and safety data, as well as potential regulatory filings.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.